Hantavirus has once again come under the spotlight of public health authorities following several recent outbreaks and an increase in cases in endemic regions. Although the overall risk remains low, the current situation highlights a key aspect for healthcare professionals: the importance of early differential diagnosis.

Current hantavirus situation

During the 2025–2026 epidemiological season, Argentina has reported a significant increase in hantavirus cases, exceeding 100 confirmed infections and showing a high mortality rate (1). This sustained rise has placed the number of infections above the outbreak threshold in several regions of the country (1).

In addition, in May 2026, an international outbreak linked to a cruise ship was reported, involving several severe cases and confirmed deaths associated with the Andes virus variant (2). This variant is particularly relevant because, unlike other hantaviruses, it can demonstrate limited person-to-person transmission in situations of close contact (2).

Despite these events, organisations such as the ECDC and the Spanish Ministry of Health consider the risk to the general population to be low, provided that epidemiological surveillance is maintained (3).

Hantavirus symptoms: why it is difficult to diagnose

One of the main challenges with hantavirus is that its early symptoms are non-specific and common to many infections. In the initial stages, patients may present with:

• Fever
• Muscle pain
• Headache
• Gastrointestinal symptoms

In some cases, the disease may rapidly progress to severe conditions such as pneumonia, acute respiratory distress syndrome, or shock (2).

This variable clinical course, together with an incubation period of up to several weeks, makes early diagnosis difficult and increases the risk of confusion with other diseases (1).

Differential diagnosis of hantavirus: diseases to rule out

Differential diagnosis of hantavirus is essential, as its symptoms can easily be mistaken for other respiratory and systemic infections. The main conditions to consider include:

• Influenza and other respiratory viruses
• COVID-19
• Viral or bacterial pneumonia
• Dengue
• Leptospirosis
• Sepsis (1)

This clinical overlap makes it essential to combine symptom assessment with epidemiological context (travel history, exposure to rodents) and specific laboratory techniques such as PCR or serology (4).

Importance of syndromic testing

In scenarios where multiple pathogens share similar symptoms, the traditional approach based on individual tests may prove insufficient. For this reason, syndromic testing has become a key diagnostic strategy.

This approach enables the simultaneous detection or exclusion of multiple infectious agents in patients with similar clinical presentations, making it particularly useful in:

• Acute respiratory infections
• Fever of unknown origin
• Emerging or imported diseases

In the case of hantavirus, the ability to rapidly rule out more common infections is essential to guide diagnosis and clinical management.

Vitassay solutions for differential diagnosis

At Vitassay, we develop molecular diagnostic solutions designed to address these clinical challenges. Yes, we are on it!

Our range of kits supports the differential diagnosis of infections with overlapping symptoms, including:

• Kits for respiratory viruses, such as influenza or SARS-CoV-2
• Assays for bacterial pathogens associated with pneumonia
• Solutions for tropical diseases, such as dengue

Thanks to these tools, laboratories can identify or rule out multiple pathogens quickly and accurately, optimising turnaround times.

Although hantavirus requires specific confirmation, having solutions that facilitate early differential diagnosis is key to improving clinical decision-making and public health response.

Sources

(1) OPS – Hantavirus, síntomas y diagnóstico diferencial: https://www.paho.org/es/temas/hantavirus

(2) ECDC – Andes Hantavirus outbreak in cruise ship: https://www.ecdc.europa.eu/en/infectious-disease-topics/hantavirus-infection/surveillance-and-updates/andes-hantavirus-outbreak

(3) Ministerio de Sanidad – Evaluación del riesgo en España: https://www.sanidad.gob.es/en/gabinete/notasPrensa.do?id=6897

(4) SEIMC – Diagnóstico microbiológico y recomendaciones clínicas: https://seimc.org/wp-content/uploads/2026/05/seimc-rc-2026-decalogo-hantavirus.pdf7

We’re finally back in the office after an intense week at WHX Labs Dubai. It’s been a busy few days, full of meetings, ideas, and good conversations.

One of the best parts of the event was catching up with our colleagues from Asia, Africa, and the Gulf region. It’s always great to share experiences and see how everyone is working to improve diagnostics in different parts of the world.

The week went by quickly, and now that we’re home, we can’t stop thinking about everything that happened. We’re already looking forward to the next edition.

We’re excited to be part of WHX Labs Dubai (formerly Medlab Dubai), continuing the tradition of bringing innovation to the world of laboratory diagnostics. As a proud manufacturer of IVD products, we invite you to visit us at booth S1.C31 and discover our solutions designed to advance healthcare.

📍 WHX Labs Dubai
📅 10–13 February 2026
📌 Booth S1.C31

This year is special: we’re celebrating 10 years committed to health!

Note it down: Stand 3D69

From 17 to 20 November, we’ll be in Düsseldorf, ready to welcome our collaborators with open arms.
We love this time of year: reconnecting, sharing ideas, and ending the year on a positive note.

If you’d like to get to know us better, see how our diagnostic tests work, or simply chat about future collaborations, just pop by!

Ten years ago, we started with a simple idea: do things right.
Create in vitro diagnostic products that are useful, clear, and reliable.
What we didn’t expect was how far they’d go.

Our kits have travelled more than we have: crossing languages, time zones, and regulations. And the best part? They keep opening doors.

Shout out to our partners: thank you for trusting us, challenging us, and helping us grow.

And hats off to our outstanding team: you make it all work.

🔬 10 years later, we’re still just as excited… and even more eager to grow.

Last week, we had the pleasure of attending ADLM 2025 , an inspiring event in a fantastic city that brought together professionals, ideas, and innovation.

It was a joy to reconnect with our dear clients and to meet so many new faces. We truly value the conversations we had and hope to stay in touch with everyone we crossed paths with.

We were also proud to present two scientific posters, sharing some of the work we’ve been developing with great enthusiasm.

Thank you to everyone who stopped by to see us. We look forward to seeing you at the next edition!

From 29^th to 31st July,  Vitassay will be exhibiting at ADLM 2025 in Chicago, the leading global event for laboratory diagnostics.

Let’s meet at Booth 942 to discover our molecular and immunodiagnostic solutions, designed to support laboratories in delivering fast and reliable

Schedule a meeting with our team to explore how our solutions can support your lab’s needs. Just email us at info@vitassay.com!

We look forward to welcoming you in Chicago!

We are proud to announce that we have been recertified in ISO 13485. This achievement shows our commitment to quality in the manufacturing of  in vitro diagnostic devices.

We will work nonstop with the same passion to deliver innovative and reliable diagnostic solutions. A big thanks to our team and the customers that continuously support us!